3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
41
Phase 2
17
Phase 3
12
Phase EARLY_PHASE1
2
Phase 4
2
Phase 1/2
2
Phase 2/3
1
Phase 1
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
3
Thoracic
2
Breast
2
Tumor-Agnostic
1
Other hematologic neoplasm
1
Lymphoid
1
Head & Neck
1
Gynecologic
1
Genitourinary
1
CNS
1
Conditions
Prostatic Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Breast Neoplasms
1
Interventions
Gemcitabine
9
Docetaxel
8
Androgen Antagonists
7
acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide
6
Magnetic Resonance Spectroscopy
6
gallium 68 PSMA-11
5
Prednisone
5
Leuprolide
5
Goserelin
5
Cisplatin
5
enzalutamide
4
bicalutamide
4
Triptorelin Pamoate
4
Radiosurgery
4
Carboplatin
4
2-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid
4
luprolide acetate gel depot
3
Flutamide
3
Celecoxib
3
valrubicin
2
pembrolizumab
2
nilutamide
2
cabazitaxel
2
abiraterone
2
Zoledronic Acid
2
Vinblastine
2
Specimen Handling
2
Radiotherapy, Intensity-Modulated
2
Radiotherapy
2
Nivolumab
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2/3
×
Standard of Care
×
Genitourinary
×
Clear all
NCT02759783
2019-08-21
CORE
Royal Marsden NHS Foundation Trust
Phase 2/3
Unknown
245 enrolled